Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both. METHODS: In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker. The primary end point was a composite of the time to cardiovascular death or a first occurrence of cardiac arrest with resuscitation; nonfatal myocardial infarction; nonfatal stroke; unplanned hospitalization for heart failure; end-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therapy with no dialysis or transplantation available or initiated; or doubling of the baseline serum creatinine level. RESULTS: The trial was stopped prematurely after the second interim efficacy analysis. After a median follow-up of 32.9 months, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20; P=0.12). Effects on secondary renal end points were similar. Systolic and diastolic blood pressures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg, respectively) and the mean reduction in the urinary albumin-to-creatinine ratio was greater (between-group difference, 14 percentage points; 95% CI, 11 to 17). The proportion of patients with hyperkalemia (serum potassium level, ≥6 mmol per liter) was significantly higher in the aliskiren group than in the placebo group (11.2% vs. 7.2%), as was the proportion with reported hypotension (12.1% vs. 8.3%) (P<0.001 for both comparisons). CONCLUSIONS: The addition of aliskiren to standard therapy with renin-angiotensin system blockade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful. (Funded by Novartis; ALTITUDE ClinicalTrials.gov number, NCT00549757.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ACE inhibitors and ARBs should not be used together and should be used with caution with spironolactone to avoid hyperkalemia or AKI.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [259]
In the citing paper
“However, combination therapy was associated with a higher rate of hyperkalemia and AKI, 85,86”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [86]
In the citing paper
“Long-term outcome trials in patients with diabetes and CKD demonstrated no kidney or cardiovascular bene fi t of RAS blockade with combined therapy to block the RAS versus the single use of RAS inhibitors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [86]
In the citing paper
“Prior trials of dual renin–angiotensin system blockade have failed to show cardiovascular or kidney protection among patients with CKD and type 2 diabetes”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [25]
In the citing paper
“markedly lower than in trials of dual RAS blockade (4.8% with combination therapy with a direct renin inhibitor and an ACE inhibitor or ARB 20 and 9.2% with dual ACE inhibitor and ARB therapy 22 )”
From Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (2020) · cites this paper as [20]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationHaffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Self-citationTelmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Self-citation
Research works printed but not linked: 1
- Pfeffer MA, 2010, Dial Cardiovasc Med, 15, 130
Cited by
Items 101–200 of 1,000
Sarafidis, P., Ferro, C. J., Morales, E., Ortiz, A., Malyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J., Fouque, D., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy407 · Cited by 204
“the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints) [76], studying the effects of combining aliskiren with ACEi or ARB, and the NEPHRON-D study examining the effects of losartan and lisinopril versus losartan alone [77] were prematurely stopped due to increased risk of complications, including hypotens…”
BackgroundThe Renin-Angiotensin-Aldosterone System and Heart Failure
Sayer, G., & Bhat, G. (2014) · Cardiology Clinics · doi:10.1016/j.ccl.2013.09.002 · Cited by 205
Chiang, C.-E., Wang, T.-D., Ueng, K.-C., Lin, T.-H., Yeh, H.-I., Chen, C.-Y., Wu, Y.-J., Tsai, W.-C., Chao, T.-H., Chen, C.-H., et al. (2015) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2014.11.005 · Cited by 199
“The trial was prematurely terminated due to a non-significant increase in primary endpoints, and an increase in adverse events, such as hyperkalemia and hypotension.(353) The RCT testing the effect of aliskiren, on top of ACE inhibitors or ARBS, in heart failure had a neutral effect, but had increased adverse events,…”
BackgroundDiabetic kidney disease: from physiology to therapeutics
Mora‐Fernández, C., Domínguez‐Pimentel, V., de Fuentes, M. M., Górriz, J. L., Martínez‐Castelao, A., & Navarro‐González, J. F. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.272328 · Cited by 194
“Patients treated with the combination experienced a 20% reduction in albuminuria as compared with participants assigned to placebo (Parving et al. 2008).”
The double challenge of resistant hypertension and chronic kidney disease
Rossignol, P., Massy, Z. A., Azizi, M., Bakris, G., Ritz, E., Covic, A., Goldsmith, D., Heine, G. H., Jager, K. J., Kanbay, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00418-3 · Cited by 194
Diabetic Nephropathy: a Tangled Web to Unweave
Magee, C., Grieve, D. J., Watson, C. J., & Brazil, D. P. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6755-9 · Cited by 190
“7 years due to the absence of change in renal outcomes and excess adverse effect risk in the aliskiren arm of the trial [80].”
BackgroundBonner, R., Albajrami, O., Hudspeth, J., & Upadhyay, A. (2020) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2020.08.004 · Cited by 177
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Nowack, C., Kolkhof, P., Ferreira, A. C., Schloemer, P., Filippatos, G., et al. (2019) · American Journal of Nephrology · doi:10.1159/000503713 · Cited by 184
The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
Muskiet, M. H. A., Smits, M. M., Morsink, L. M., & Diamant, M. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.272 · Cited by 181
Bandak, G., Sang, Y., Gasparini, A., Chang, A. R., Ballew, S. H., Evans, M., Arnlov, J., Lund, L. H., Inker, L. A., Coresh, J., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005428 · Cited by 181
“Although many of the risk characteristics have been previously identified, an existing risk score did not incorporate sex or potassium, one of the strongest observed risk factors.(24,25,29) In our study, male sex was also a risk factor for the development of hyperkalemia, potentially because of lower intake of potassi…”
Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Kintscher, U., Bakris, G. L., & Kolkhof, P. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15747 · Cited by 173
Abraham, H. M. A., White, C. M., & White, W. B. (2015) · Drug Safety · doi:10.1007/s40264-014-0239-7 · Cited by 175
Therapeutic approaches to diabetic nephropathy—beyond the RAS
Fernandez-Fernandez, B., Ortiz, A., Gomez-Guerrero, C., & Egido, J. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.74 · Cited by 170
Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision)
Wang, J. (2025) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2025.01.008 · Cited by 196
The Renin Angiotensin Aldosterone System in Obesity and Hypertension
Cabandugama, P. K., Gardner, M. J., & Sowers, J. R. (2017) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.08.009 · Cited by 168
“This once again solidified the notion that the use of an RAAS antagonist was protective against the insulin resistance properties of the diuretic, when used concurrently.(38)”
MethodAlbuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View
Lambers Heerspink, H. J., & Gansevoort, R. T. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11511114 · Cited by 168
Kim, H.-L., Lee, E. M., Ahn, S. Y., Kim, K.-I., Kim, H. C., Kim, J. H., Lee, H.-Y., Lee, J. H., Park, J.-M., Cho, E. J., et al. (2023) · Clinical Hypertension · doi:10.1186/s40885-023-00234-9 · Cited by 164
“These results were similar in combination therapy with ARBs and direct renin inhibitors [149].”
ResultThe New Biology of Diabetic Kidney Disease—Mechanisms and Therapeutic Implications
Lytvyn, Y., Bjornstad, P., van Raalte, D. H., Heerspink, H. L., & Cherney, D. Z. I. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz010 · Cited by 165
Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease
Lazich, I., & Bakris, G. L. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.04.008 · Cited by 164
The effect of RAAS blockade on the progression of diabetic nephropathy
Roscioni, S. S., Heerspink, H. J. L., & de Zeeuw, D. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.251 · Cited by 162
Škrtić, M., Yang, G. K., Perkins, B. A., Soleymanlou, N., Lytvyn, Y., von Eynatten, M., Woerle, H. J., Johansen, O. E., Broedl, U. C., Hach, T., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3396-4 · Cited by 159
“In light of findings from the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET), Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (ALTITUDE) and Veterans Affairs Nephropathy in Diabetes trial (VA-NEPHRON-D), which use strategies of dual RAAS…”
BackgroundApplication of micro RNA s in diagnosis and treatment of cardiovascular disease
Wronska, A., Kurkowska‐Jastrzebska, I., & Santulli, G. (2015) · Acta Physiologica · doi:10.1111/apha.12416 · Cited by 158
Hypertension with diabetes mellitus complications
Yamazaki, D., Hitomi, H., & Nishiyama, A. (2018) · Hypertension Research · doi:10.1038/s41440-017-0008-y · Cited by 188
“patients with type 2 diabetes at high risk for cardiovascular and renal events [61].”
Immunologic Effects of the Renin-Angiotensin System
Crowley, S. D., & Rudemiller, N. P. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016101066 · Cited by 153
LRG1 Promotes Diabetic Kidney Disease Progression by Enhancing TGF-β–Induced Angiogenesis
Hong, Q., Zhang, L., Fu, J., Verghese, D. A., Chauhan, K., Nadkarni, G. N., Li, Z., Ju, W., Kretzler, M., Cai, G., et al. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018060599 · Cited by 164
The genetics of diabetic complications
Ahlqvist, E., van Zuydam, N. R., Groop, L., & McCarthy, M. I. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.37 · Cited by 162
Salem, C. B., Badreddine, A., Fathallah, N., Slim, R., & Hmouda, H. (2014) · Drug Safety · doi:10.1007/s40264-014-0196-1 · Cited by 165
Škrtić, M., & Cherney, D. Z. I. (2015) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0000000000000084 · Cited by 148
Resistant Hypertension: A Review of Diagnosis and Management
Vongpatanasin, W. (2014) · JAMA · doi:10.1001/jama.2014.5180 · Cited by 146
Novel RAAS agonists and antagonists: clinical applications and controversies
Romero, C. A., Orias, M., & Weir, M. R. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.6 · Cited by 147
“58 However, in this trial, the combination of aliskiren and losartan did not show any benefits on cardiovascular or renal outcomes versus losartan alone, and dual therapy was associated with an increased rate of adverse events.”
BackgroundA perspective on chronic kidney disease progression
Zhong, J., Yang, H., & Fogo, A. B. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00266.2016 · Cited by 169
“Optimize and maximize RAAS blockade RAAS blocker Renin inhibitor, ACEI, ARB, Aldosterone synthesis inhibitor (25, 57, 66, 73, 77)”
BackgroundACE Inhibitor-Induced Angioedema: a Review
Kostis, W. J., Shetty, M., Chowdhury, Y. S., & Kostis, J. B. (2018) · Current Hypertension Reports · doi:10.1007/s11906-018-0859-x · Cited by 191
Mechanisms of food protein-derived antihypertensive peptides other than ACE inhibition
Udenigwe, C. C., & Mohan, A. (2014) · Journal of Functional Foods · doi:10.1016/j.jff.2014.03.002 · Cited by 144
Mc Causland, F. R., Claggett, B. L., Vaduganathan, M., Desai, A. S., Jhund, P., de Boer, R. A., Docherty, K., Fang, J., Hernandez, A. F., Inzucchi, S. E., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2022.4210 · Cited by 131
Self-citationProteinuria and its relation to cardiovascular disease
Delles, C., & Currie, G. E. (2013) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s40522 · Cited by 164
Capítulo 1 - Conceituação, Epidemiologia e Prevenção Primária
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160151 · Cited by 228
on behalf of the PERL Consortium, Maahs, D. M., Caramori, L., Cherney, D. Z. I., Galecki, A. T., Gao, C., Jalal, D., Perkins, B. A., Pop-Busui, R., Rossing, P., et al. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0381-0 · Cited by 138
Perkovic, V., Agarwal, R., Fioretto, P., Hemmelgarn, B. R., Levin, A., Thomas, M. C., Wanner, C., Kasiske, B. L., Wheeler, D. C., Groop, P.-H., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.09.010 · Cited by 136
“, hyperkalemia, acute kidney injury [AKI]).(12,13,52) More recently, the VA-NEPHRON-D trial(10) evaluated losartan alone versus losartan and lisinopril in stage 2 to 3 DKD with”
BackgroundWhaley‐Connell, A. T., & Sowers, J. R. (2017) · Kidney International · doi:10.1016/j.kint.2016.12.034 · Cited by 143
Blood pressure control in type 2 diabetic patients
Grossman, A., & Grossman, E. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0485-3 · Cited by 161
“Combining two RAAS blockers is discouraged based on the discouraging results of the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints (ALTITUDE) and the ONTARGET trials [34, 66].”
BackgroundSiddiqi, F. S., & Advani, A. (2013) · Diabetes · doi:10.2337/db13-0795 · Cited by 138
“Similarly, although the antialbuminuric properties of the direct renin inhibitor, aliskiren, were effectively demonstrated in the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial (7), the CV outcome study for aliskiren, Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE), was…”
BackgroundSasso, F. C., Pafundi, P. C., Simeon, V., De Nicola, L., Chiodini, P., Galiero, R., Rinaldi, L., Nevola, R., Salvatore, T., Sardu, C., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01343-1 · Cited by 129
“Notably, during intervention phase the percentage of subjects who had to suspend treatment with drugs active on the RAS due to persistent side effects was low and was similar to what was recorded in the Altitude study [38].”
ResultOtt, C., Mahfoud, F., Schmid, A., Toennes, S. W., Ewen, S., Ditting, T., Veelken, R., Ukena, C., Uder, M., Böhm, M., et al. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000556 · Cited by 129
“The direct renin inhibitor aliskiren was discontinued in six patients because of regulatory warning [28] related to the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints study [4].”
Combination therapy for kidney disease in people with diabetes mellitus
van Raalte, D. H., Bjornstad, P., Cherney, D. Z. I., de Boer, I. H., Fioretto, P., Gordin, D., Persson, F., Rosas, S. E., Rossing, P., Schaub, J. A., et al. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00827-z · Cited by 127
“…an angiotensin receptor blocker (ARB) (VA-nephron trial) 10 and direct renin inhibition using aliskiren in combination with ACE inhibitor or ARB therapy (ALTITUDE trial) 11 did not improve kidney outcomes and were associated with adverse events such as hyperkalaemia and acute kidney injury (AKI).”
Self-citationBhandari, S., Ives, N., Brettell, E. A., Valente, M., Cockwell, P., Topham, P. S., Cleland, J. G., Khwaja, A., & El Nahas, M. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv346 · Cited by 127
Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD
Sinha, A. D., & Agarwal, R. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04330418 · Cited by 135
Bianchi, S., Aucella, F., Nicola, L. D., Genovesi, S., Paoletti, E., & Regolisti, G. (2019) · Journal of Nephrology · doi:10.1007/s40620-019-00617-y · Cited by 145
Endoplasmic reticulum stress drives proteinuria-induced kidney lesions via Lipocalin 2
Karoui, K. E., Viau, A., Dellis, O., Bagattin, A., Nguyen, C., Baron, W., Burtin, M., Broueilh, M., Heidet, L., Mollet, G., et al. (2016) · Nature Communications · doi:10.1038/ncomms10330 · Cited by 142
Hypertension and Stroke: Epidemiological Aspects and Clinical Evaluation
Pistoia, F., Sacco, S., Degan, D., Tiseo, C., Ornello, R., & Carolei, A. (2015) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-015-0115-2 · Cited by 143
“strokes [55].”
Neuen, B. L., Oshima, M., Perkovic, V., Agarwal, R., Arnott, C., Bakris, G., Cannon, C. P., Charytan, D. M., Edwards, R., Górriz, J. L., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab497 · Cited by 123
“2 mmol/L).(8,30,31) These results should be interpreted in light of certain limitations.”
BackgroundChronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Mende, C. W. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01994-2 · Cited by 147
Updated National and International Hypertension Guidelines: A Review of Current Recommendations
Kjeldsen, S., Feldman, R. D., Lisheng, L., Mourad, J.-J., Chiang, C.-E., Zhang, W., Wu, Z., Li, W., & Williams, B. (2014) · Drugs · doi:10.1007/s40265-014-0306-5 · Cited by 126
“The only drug combination that is advised against by all guidelines is combining ACEI and ARB, due to the increased risk of end-stage renal disease and stroke identified by the ONTARGET (an ARB in combination with an ACEI) [39] and ALTITUDE (direct renin inhibitor, aliskiren, in combination with ACEI or ARB) studies,…”
BackgroundRenin angiotensin aldosterone inhibition in the treatment of cardiovascular disease
Ferrario, C. M., & Mullick, A. E. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.020 · Cited by 122
Oellgaard, J., Gæde, P., Rossing, P. R., Persson, F., Parving, H., & Pedersen, O. B. (2017) · Kidney International · doi:10.1016/j.kint.2016.11.023 · Cited by 124
Self-citation(2022) · PubMed Central · doi:10.6515/acs.202205_38(3).20220321a · Cited by 117
Multifunctional Role of Chymase in Acute and Chronic Tissue Injury and Remodeling
Dell’Italia, L. J., Collawn, J. F., & Ferrario, C. M. (2018) · Circulation Research · doi:10.1161/circresaha.117.310978 · Cited by 113
“The need for new therapeutic targets is now fueled by the failure of dual RAS blockade with the addition of the direct renin inhibitor aliskiren in patients with chronic heart failure(13,14) or with type II diabetes mellitus.(15) Likewise, the success of neprilysin blockade added to AT 1 receptor blockade in patients…”
BackgroundThe renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure
Pugliese, N. R., Masi, S., & Taddei, S. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09855-5 · Cited by 120
Cooper, M. E., Perkovic, V., McGill, J. B., Groop, P.-H., Wanner, C., Rosenstock, J., Hehnke, U., Woerle, H.-J., & von Eynatten, M. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.03.024 · Cited by 110
“For example, a recent trial targeting dual blockade of the RAS by combining the novel renin inhibitor aliskiren with the established classes of either ACE inhibitors or ARBs in patients with type 2 diabetes supports such a possibility.(11) This trial had to be terminated prematurely, partially as a result of excess ri…”
ResultNovel Therapies for Diabetic Kidney Disease
Alicic, R. Z., & Tuttle, K. R. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.01.007 · Cited by 113
Hypertension in patients with type 2 diabetes mellitus: Targets and management
Pavlou, D. I., Paschou, S. Α., Anagnostis, P. G., Spartalis, Μ., Spartalis, E. D., Vryonidou, A., Tentolouris, N., & Siasos, G. (2018) · Maturitas · doi:10.1016/j.maturitas.2018.03.013 · Cited by 126
Up-Date on Diabetic Nephropathy
Pelle, M. C., Provenzano, M., Busutti, M., Porcu, C. V., Zaffina, I., Stanga, L., & Arturi, F. (2022) · Life · doi:10.3390/life12081202 · Cited by 129
Catalá-López, F., Macías Saint-Gerons, D., González-Bermejo, D., Rosano, G. M., Davis, B. R., Ridao, M., Zaragoza, A., Montero-Corominas, D., Tobías, A., de la Fuente-Honrubia, C., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001971 · Cited by 109
“The Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (ALTITUDE) [22] trial was stopped prematurely because the addition of the DR inhibitor aliskiren to standard therapy with RAS blockade did not result in a decrease of cardiovascular and renal events and increased the risk of advers…”
BackgroundMethodAgarwal, R., Tu, W., Farjat, A. E., Farag, Y. M. K., Toto, R., Kaul, S., Lawatscheck, R., Rohwedder, K., Ruilope, L. M., Rossing, P., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m23-1023 · Cited by 109
Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression
Wang, N., & Zhang, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063086 · Cited by 139
“Currently, a phase II study of pirfenidone for renal fibrosis is ongoing (NCT04258397) and will be completed by 2024. and demonstrated to be even harmful [127].”
BackgroundThe role of SBA-15 in drug delivery
Vavsari, V. F., Ziarani, G. M., & Badiei, A. (2015) · RSC Advances · doi:10.1039/c5ra17780d · Cited by 110
Neprilysin inhibition in chronic kidney disease
Judge, P., Haynes, R., Landray, M., & Baigent, C. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu269 · Cited by 118
“In the general population, RASi reduce cardiovascular events, and meta-analyses suggest that the mechanism of this benefit is not simply blood pressure (BP) reduction [7, 8].”
ResultInfluentialDiabetic nephropathy: landmark clinical trials and tribulations
Chan, G. C. W., & Tang, S. C. W. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu411 · Cited by 117
“ALTITUDE [21] 8561 T2DM RAS blockade plus aliskiren versus placebo Terminated at 2.”
BackgroundInfluentialNew pharmacological strategies for protecting kidney function in type 2 diabetes
Muskiet, M. H. A., Wheeler, D. C., & Heerspink, H. J. L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30263-8 · Cited by 107
‘Progressive diabetic nephropathy. How useful is microalbuminuria?: contra’
MacIsaac, R. J., Ekinci, E. I., & Jerums, G. (2014) · Kidney International · doi:10.1038/ki.2014.98 · Cited by 111
Comprehensive approach to diabetic nephropathy
Satirapoj, B., & Adler, S. G. (2014) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2014.08.001 · Cited by 123
“Some trials resulted in an increase in adverse events (aminoguanidine, aliskerin, bardoxolone) [88,92,93].”
BackgroundNovel insights into the pathophysiology and clinical aspects of diabetic nephropathy
Ilyas, Z., Chaiban, J. T., & Krikorian, A. (2017) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-017-9422-3 · Cited by 115
Chronic Kidney Disease in Diabetes
McFarlane, P. A., Cherney, D. Z. I., Gilbert, R. E., & Senior, P. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.11.004 · Cited by 143
Clinical Challenges in Diagnosis and Management of Diabetic Kidney Disease
Stanton, R. C. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.10.050 · Cited by 115
“In late 2011, the study was stopped prematurely by the data safety and monitoring board for the study due to the occurrence of excess adverse events (nonfatal stroke, hyperkalemia, hypotension, and decreased kidney function).(99) Considering that generic forms of ACE inhibitors provide a much more cost-effective solut…”
BackgroundAgarwal, R., Anker, S. D., Bakris, G., Filippatos, G., Pitt, B., Rossing, P., Ruilope, L., Gebel, M., Kolkhof, P., Nowack, C., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa294 · Cited by 103
Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report
Weir, M. R., Lakkis, J. I., Jaar, B. G., Rocco, M. V., Choi, M. J., Kramer, H., & Ku, E. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.06.010 · Cited by 110
Chronic Kidney Disease in Diabetes
McFarlane, P. A., Gilbert, R. E., MacCallum, L., & Senior, P. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.037 · Cited by 115
“management of diabetes and CKD [Grade A, Level 1(89,90)].”
BackgroundAlexandrou, M.-E., Papagianni, A., Tsapas, A., Loutradis, C., Boutou, A., Piperidou, A., Papadopoulou, D., Ruilope, L., Bakris, G., & Sarafidis, P. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002187 · Cited by 101
“The magnitude of albuminuria reduction in these trials predicted the reduction in the primary outcome [81,82].”
BackgroundMechanisms of diabetic kidney disease and established and emerging treatments
Leon, V. M., Hilburg, R., & Suszták, K. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01171-3 · Cited by 127
“The Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (ALTITUDE) investigated the combination of standard RAS blockade with aliskiren, a direct renin inhibitor, in patients with T2DM 107 .”
Blood pressure lowering efficacy of renin inhibitors for primary hypertension
Musini, V. M., Lawrence, K. A., Fortin, P. M., Bassett, K., & Wright, J. M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007066.pub3 · Cited by 98
2019 Chinese guideline for the management of hypertension in the elderly.
Hua, Q., Fan, L. H., & Li, J. (2019) · PubMed Central · doi:10.11909/j.issn.1671-5411.2019.02.001 · Cited by 113
Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Rinaldi, L., Coviello, F., Martino, A. D., Albanese, G., Marfella, R., Sardu, C., et al. (2021) · Biomolecules · doi:10.3390/biom11121834 · Cited by 102
CARDIOVASCULAR RISK AND CHRONIC KIDNEY DISEASE: CARDIO-NEPHROPROTECTION STRATEGIES
MOISEEV, V., Mukhin, N. A., Smirnov, A. V., Kobalava, J. D., Bobkova, I. N., Вадимовна, В. С., Алексеевна, Е. М., Kozlovskaya, L. V., Швецов, М. Ю., Shestakova, M. V., et al. (2014) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2014-8-7-37 · Cited by 142
Targeting the renin–angiotensin–aldosterone system in heart failure
Lang, C. C., & Struthers, A. D. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.196 · Cited by 101
Hypertension: Pathophysiology and Treatment
Delacroix, S., & Chokka, R. G. (2014) · Journal of Neurology & Neurophysiology · doi:10.4172/2155-9562.1000250 · Cited by 118
“However, further studies assessing the utility of the latter group is imperative considering the ambiguity of treatment efficacy and the potential side effects in specific patient subgroups [86-89].”
BackgroundConcomitant Diabetes Mellitus and Heart Failure
Dei, A., Fonarow, G. C., Gheorghiade, M., & Butler, J. (2014) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2014.09.002 · Cited by 94
de Sousa, A. G. P., Cabral, J. V., El-Feghaly, W. B., sousa, L. K. L., & Nunes, A. B. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i5.101 · Cited by 94
Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease
Bernardi, S., Michelli, A., Zuolo, G., Candido, R., & Fabris, B. (2016) · Journal of Diabetes Research · doi:10.1155/2016/8917578 · Cited by 104
“However, similarl to what was reported in the ONTARGET trial, the ALTITUDE study has demonstrated that the simultaneous administration of Aliskiren with an ACE inhibitor or an ARB should be avoided [213].”
ResultKolkhof, P., Joseph, A., & Kintscher, U. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105859 · Cited by 94
Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome
López-Jaramillo, P., Sánchez, R. A., Diaz, M., Cobos, L., Bryce, A., Parra Carrillo, J. Z., Lizcano, F., Lanas, F., Sinay, I., Sierra, I. D., et al. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835c5444 · Cited by 90
Oellgaard, J., Gæde, P., Rossing, P., Rørth, R., Køber, L., Parving, H.-H., & Pedersen, O. (2018) · Diabetologia · doi:10.1007/s00125-018-4642-y · Cited by 86
“In the following studies (all including patients with type 2 diabetes and micro- or macroalbuminuria), heart failure was more common than other cardiovascular complications: reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) [21], the Irbesartan Diabetic Nephropathy Trial (IDNT) [22],…”
Self-citationTherapeutic Insights in Chronic Kidney Disease Progression
Shabaka, A., Cases‐Corona, C., & Juarez, G. M. F. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.645187 · Cited by 96
Verbeke, F., Lindley, E., Bortel, L. M. V., Vanholder, R. C., London, G. M., Cochat, P., Więcek, A., Fouque, D. P., & Biesen, W. V. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft321 · Cited by 86
“The ERBP Work Group considers the NICE guidance to be reasonable, as some large trials point to increased risk of harm (hyperkalaemia) when blocking the renin–angiotensin–aldosterone axis at different levels [6, 7] and studies proving any benefit from this strategy are lacking.”
BackgroundMicroalbuminuria: target for renoprotective therapy PRO
Roscioni, S. S., Heerspink, H. J. L., & de Zeeuw, D. (2014) · Kidney International · doi:10.1038/ki.2013.490 · Cited by 93
Heerspink, H. J. L., Andress, D. L., Bakris, G. L., Brennan, J. J., Correa‐Rotter, R., Dey, J., Hou, F. F., Kitzman, D. W., Kohan, D. E., Makino, H., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13245 · Cited by 90
Self-citationHypertension in chronic kidney disease—treatment standard 2023
Georgianos, P. I., & Agarwal, R. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad118 · Cited by 116
New Therapies for Diabetic Kidney Disease
Himmelfarb, J., & Tuttle, K. R. (2013) · New England Journal of Medicine · doi:10.1056/nejme1313104 · Cited by 84
Improvements in the Management of Diabetic Nephropathy
Dounousi, E. C., Duni, Α., Leivaditis, K., Vaios, V., Eleftheriadis, T., & Liakopoulos, V. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.119 · Cited by 89
An Update on the Use of Animal Models in Diabetic Nephropathy Research
Betz, B. B., & Conway, B. R. (2016) · Current Diabetes Reports · doi:10.1007/s11892-015-0706-2 · Cited by 88
Unraveling Cardiovascular Risk in Renal Patients: A New Take on Old Tale
Provenzano, M., Coppolino, G., Nicola, L. D., Serra, R., Garofalo, C., Andreucci, M., & Bolignano, D. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00314 · Cited by 88
“Similar findings were reported from individuals with eGFR <60 ml/min/1.73 m2 selected from insurance-based health organizations (i.e., Kaiser Permanente Northwest), or Veterans Affair elderly with proteinuria or type 2 diabetes (Keith et al., 2004; Patel et al., 2005).”
ResultInfluentialMineralocorticoid Receptor Antagonism in Chronic Kidney Disease
Georgianos, P. I., & Agarwal, R. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.05.027 · Cited by 87
Metadata
- Authors
- Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., Richard, A., Xiang, Z., Brunel, P., & Pfeffer, M. A.
- Affiliations
- University of Copenhagen (DK)
- Brigham and Women's Hospital (US)
- The University of Texas at San Antonio Health Science Center (US)
- Imperial College London (GB)
- Steno Diabetes Centers (DK)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-12-06
- Volume
- 367
- Issue
- 23
- Pages
- 2204-2213
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138862624
- Cited by
- 1,319
- References
- 40
- Citations by year
- 2026: 30 · 2025: 41 · 2024: 52 · 2023: 68 · 2022: 61 · 2021: 75 · 2020: 73 · 2019: 96 · 2018: 93 · 2017: 124 · 2016: 117 · 2015: 151 · 2014: 166 · 2013: 159 · 2012: 11
- FWCI
- 100.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- IRIS (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Open Access CRIS of the University of Bern
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- aliskiren, type 2 diabetes, chronic kidney disease, renin-angiotensin system blockade, ACE inhibitors, angiotensin receptor blockers, cardiovascular events, end-stage renal disease, hyperkalemia, hypotension, albumin-creatinine ratio, blood pressure reduction, cardiorenal outcomes
- MeSH terms
- Renin Inhibitors, Aged, Amides, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Fumarates, Humans, Hyperkalemia, Hypokalemia, Kidney Diseases, Male, Middle Aged, Patient Dropouts, Treatment Failure, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.